Advertisement
U.S. markets open in 3 hours 42 minutes
  • S&P Futures

    5,205.75
    -9.00 (-0.17%)
     
  • Dow Futures

    39,176.00
    -47.00 (-0.12%)
     
  • Nasdaq Futures

    18,193.00
    -38.50 (-0.21%)
     
  • Russell 2000 Futures

    2,042.90
    -6.90 (-0.34%)
     
  • Crude Oil

    82.47
    -0.25 (-0.30%)
     
  • Gold

    2,156.40
    -7.90 (-0.37%)
     
  • Silver

    25.11
    -0.15 (-0.61%)
     
  • EUR/USD

    1.0842
    -0.0034 (-0.31%)
     
  • 10-Yr Bond

    4.3400
    0.0000 (0.00%)
     
  • Vix

    14.54
    +0.21 (+1.47%)
     
  • GBP/USD

    1.2673
    -0.0056 (-0.44%)
     
  • USD/JPY

    150.6230
    +1.5250 (+1.02%)
     
  • Bitcoin USD

    63,521.84
    -4,537.94 (-6.67%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,720.19
    -2.36 (-0.03%)
     
  • Nikkei 225

    40,003.60
    +263.20 (+0.66%)
     

Ambrx Shares Surge After Encouraging Early Safety, Efficacy Data From Breast Cancer Candidate

  • Ambrx Biopharma Inc (NASDAQ: AMAM) announced preliminary safety and efficacy data from its Phase 2 ACE‑Breast-03 study.

  • The data presented demonstrated a 51.7% overall response rate (ORR) and 100% disease control rate (DCR) after treatment with ARX788 in HER2-positive mBC patients who are resistant or refractory to T-DM1.

  • ACE-Breast-03 is a Phase 2 study of ARX788 for patients whose metastatic disease is resistant or refractory to T-DXd, T-DM1, or tucatinib-containing regimens.

  • Related: Ambrx Biopharma Stops Working On Breast Cancer Candidate, Cites Competition As The Reason.

  • Patients had a median time on therapy of 7.2 months, and treatment remains ongoing.

  • None of the patients experienced drug-related serious adverse events (SAEs), and all adverse events (AEs) were well tolerated, with no treatment discontinuations from AEs.

  • Two Phase 3 studies and one registration-enabled Phase 2 study with ARX788 conducted by Amrbrx's partner, NovoCodex Biopharmaceuticals, are ongoing in China, with projected readouts in 2023.

  • Price Action: AMAM shares are up 180.6% at $1.15 during the premarket session on the last check Friday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement